We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.19%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$522M
AUM Growth
-$148M
Cap. Flow
-$183M
Cap. Flow %
-35.1%
Top 10 Hldgs %
68.85%
Holding
172
New
42
Increased
30
Reduced
27
Closed
64

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.7M
2
AZN icon
AstraZeneca
AZN
+$11.5M
3
XWEL icon
XWELL
XWEL
+$3.81M
4
RVPH
REVIVA PHARMA HLDGS INC
RVPH
+$3.63M
5
CVM icon
CEL-SCI Corp
CVM
+$2.66M

Top Sells

Rank Stock Value
1
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$4.87M
2
IMMU
Immunomedics Inc
IMMU
+$4.25M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.12M
4
SPI
SPI Energy Co., Ltd. Ordinary Shares
SPI
+$3.57M
5
RMTI icon
Rockwell Medical
RMTI
+$3.04M

Sector Composition

Rank Sector Weight
1 Healthcare 17.64%
2 Industrials 0.71%
3 Technology 0.22%
4 Consumer Discretionary 0.14%
5 Consumer Staples 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CVM icon
26
CEL-SCI Corp
CVM
$21M
$3.62M 0.69%
10,339
+6,743
+188% +$2.66M
TRIL
27
PUT
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.5M 0.67%
+2,379
New +$34.3K
MRTX
28
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.19M 0.61%
+145
New +$31.3K
RVPH
29
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$3.13M 0.6%
+17,915
New +$3.63M
INO icon
30
PUT
Inovio Pharmaceuticals
INO
$84.7M
$2.81M 0.54%
264
+62
+31% +$8.25K
AMRN
31
CALL
Amarin Corp
AMRN
$293M
$2.55M 0.49%
260
+6
+2% +$578
INO icon
32
Inovio Pharmaceuticals
INO
$84.7M
$2.53M 0.48%
23,782
+13,375
+129% +$1.78M
IONS icon
33
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$2.42M 0.46%
428
– –
PULM icon
34
Pulmatrix
PULM
$6.14M
$2.35M 0.45%
98,765
+11,732
+13% +$279K
AFIB
35
DELISTED
Acutus Medical Inc
AFIB
$2.23M 0.43%
77,500
+27,844
+56% +$754K
NMRD
36
DELISTED
Nemaura Medical, Inc. Common Stock
NMRD
$1.86M 0.36%
494,297
-119,468
-19% -$461K
TRIL
37
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.76M 0.34%
+119,996
New +$1.73M
GLBS icon
38
Globus Maritime Ltd
GLBS
$60.9M
$1.66M 0.32%
+290,535
New +$2.51M
DXR icon
39
Daxor
DXR
$62.2M
$1.6M 0.31%
128,398
+5,992
+5% +$83K
SPCB icon
40
SuperCom
SPCB
$65.9M
$1.52M 0.29%
7,400
– –
CVM.WS
41
CALL
DELISTED
Cel-Sci Corp Series S
CVM.WS
$1.48M 0.28%
1,271
-3,334
-72% -$3.89M
TCDA
42
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.41M 0.27%
+200,437
New +$1.54M
NMTR
43
PUT
DELISTED
9 Meters Biopharma
NMTR
$1.27M 0.24%
741
+652
+733% +$10.9K
MRNS
44
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.23M 0.24%
+100,800
New +$1.41M
IONS icon
45
PUT
Ionis Pharmaceuticals
IONS
$9.14B
$1.2M 0.23%
212
– –
ASTC icon
46
Astrotech Corp
ASTC
$12.9M
$1.12M 0.22%
+21,143
New +$1.18M
ITCI
47
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.11M 0.21%
35,000
-80,000
-70% -$2.1M
BCLI
48
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.07M 0.21%
158
-138
-47% -$18.8K
AUPH icon
49
PUT
Aurinia Pharmaceuticals
AUPH
$1.92B
$1.05M 0.2%
+757
New +$11K
HMCOU
50
DELISTED
HumanCo Acquisition Corp. Unit
HMCOU
$1.05M 0.2%
+95,050
New +$1.05M
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2020 Portfolio in Review

As of Q4 2020, Sabby Management held 172 positions worth $522M, down 22% from $670M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sabby Management withdrew a net $183M in Q4 2020, closing 64 positions and reducing 27 holdings. Its most notable exit was Sorrento Therapeutics, Inc., an estimated $4.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 12% a quarter earlier, followed by Industrials and Technology.

Against the trend, Sabby Management opened a new position in REVIVA PHARMA HLDGS INC worth $3.13M.

  • Sabby Management's largest Q4 2020 buy was REVIVA PHARMA HLDGS INC: 17,915 shares worth $3.13M.
  • Sabby Management added most to Biogen in Q4 2020, an estimated $18.7M increase.
  • Sabby Management's biggest Q4 2020 reduction was Rockwell Medical, cutting an estimated $3.04M.
  • Sabby Management fully exited Sorrento Therapeutics, Inc. in Q4 2020, selling an estimated $4.87M.
  • Sabby Management's ten largest holdings make up 69% of its $522M portfolio in Q4 2020.
  • Sabby Management opened 42 new positions and closed 64 in Q4 2020.
  • Sabby Management's portfolio value fell 22% quarter-over-quarter to $522M.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.